Although our findings did not reveal any overt negative effects of BRQ on the CD8+ T cell response in the context of our preclinical cancer models, DHODH inhibitors are being used clinically in the context of autoimmune disorders to dampen autoimmune T cell activity. The gene discussed is CD8A; the disease is cancer.